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AngiogenesisProtein tyrosine kinase 7 (PTK7) is amember of the defective receptor protein tyrosine kinase familywhich lacks
catalytic activity. Expression of PTK7 is increased in various cancers but its role in carcinogenesis is not well
understood. We previously showed that disruption of PTK7 function suppresses VEGF-induced angiogenic
phenotypes in HUVECs and mice. Here, we investigated molecular mechanisms for modulating VEGF-induced
physiological effects by PTK7. Treatment with a high concentration of extracellular domain of PTK7 (soluble
PTK7; sPTK7) or knockdown of PTK7 inhibited VEGF-induced phosphorylation of kinase insert domain receptor
(KDR) but did not inhibit phosphorylation of fms-related tyrosine kinase 1 (FLT-1) in HUVECs. PTK7, more spe-
ciﬁcally sPTK7, interacted with KDR but not with FLT-1 in HUVECs and HEK293 cells. In vitro binding assay
showed that sPTK7 formed oligomers with the extracellular domain of KDR (sKDR) up to an approximately
1:3 molar ratio, and vice versa. sPTK7 at lower molar ratios than sKDR enhanced the binding of VEGF to sKDR.
At the same or higher molar ratios, it reduced the binding of VEGF to sKDR. Increasing concentrations of sPTK7
or increasing levels of PTK7 expression ﬁrst increased and then decreased VEGF-induced KDR phosphorylation,
migration, and capillary-like tube formation of HUVECs, as well as in vivo angiogenesis. Taken together, our
data demonstrates that PTK7 regulates the activity of KDR biphasically by inducing oligomerization of KDR mol-
ecules at lower concentrations and by surrounding KDR molecules at higher concentrations.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
A subgroup of receptor protein tyrosine kinases (RPTKs) is defective
in tyrosine kinase activity because of alterations in motifs important for
catalytic activity [1]. Such defective RPTKs include protein tyrosine
kinase 7 (PTK7), HER3 (ErbB3), EphA10, EphB6, and Ryk. Despite their
lack of kinase activity, some of these defective RPTKs are known to pro-
mote signal transduction by interacting with other proteins. For exam-
ple, HER3 bound to neuregulin forms heterodimers with other EGFR
family members and activates downstream signals, such as PI3-kinase
and MAP kinases [2,3]. Ryk interacts with Eph receptors, EphB2 and
EphB3, and regulates cell migration during craniofacial and cortical de-
velopment [4–6]. Ryk also functions as a co-receptor forWnt signalmol-
ecules and modulates Wnt signaling pathways during neural
development [7,8].
PTK7, also known as colon carcinoma kinase 4 (CCK-4), is composed
of an extracellular domain with seven immunoglobulin-like loops, aHUVEC, human umbilical vein
K7, protein tyrosine kinase 7;
othelial growth factor.
try, College of Life Science and
lic of Korea. Tel.: +82 2 2123transmembrane domain, and a defective tyrosine kinase domain
[9–12].DrosophilaDtrk/OTK and chickKLG,which are likely orthologues
of human PTK7, contribute to repulsive axon guidance in Drosophila
development and ventricle segment formation during chick cardiac
morphogenesis through interaction with plexins, which are receptors
for semaphorins [13,14]. Mammalian PTK7 is known to regulate planar
cell polarity (PCP) signaling, based on the ﬁnding that mice homozy-
gous for a truncated PTK7 gene were perinatally lethal, with failure of
neural closure and misorientation of the stereociliary bundle [15].
Recently it was reported that PTK7 also regulates canonical and non-
canonical Wnt signaling pathways [16,17].
PTK7 expression is elevated in various cancers, including esophageal
squamous cell carcinoma and colon cancer [18–20]. Conversely, its
expression is decreased in other cancers such as metastatic melanoma
and ovarian carcinoma [21,22]. These ﬁndings suggest that its expression
level is not directly related to tumorigenesis. Interestingly, we previously
found that PTK7 is shed byADAM17 and further cleaved byγ-secretase in
colon cancer cells [23]. The cleaved PTK7 cytosolic domain translocates
from plasma membrane to the nucleus and enhances tumorigenesis.
PTK7 mRNA levels are modulated during vascular endothelial
growth factor (VEGF)-induced capillary-like tube formation by human
umbilical vein endothelial cells (HUVECs) [24]. Functional disruption
of PTK7 by treatment with the PTK7 extracellular domain (soluble
PTK7; sPTK7) as a decoy receptor or knockdown of PTK7 decreased
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angiogenesis in vivo [24]. Therefore, PTK7 at the plasma membrane
probably plays an important role in VEGF-mediated signaling. To fur-
ther understand the effect of PTK7 on signaling pathways induced by
VEGF, we identiﬁedmolecules interactingwith PTK7.We then analyzed
the changes in the activity of PTK7-interacting proteins upon exposure
to different PTK7 levels, as well as the effects of different PTK7 levels on
migration and tube-formation by HUVECs, and on angiogenesis in vivo.
Based on the results, we propose a model for the action of PTK7.
2. Materials and methods
2.1. Antibodies
The following antibodies were used: anti-FLT-1, anti-phospho-Erk,
anti-Erk, anti-p38, anti-VEGF, and anti-β-actin antibodies from Santa
Cruz Biotechnology (Santa Cruz, CA, USA); anti-phospho-KDR (Y951),
anti-KDR, anti-phospho-p38, anti-phospho-Akt (S473), anti-Akt, anti-
phospho-eNOS (S1177), anti-eNOS, anti-phospho-JNK, and anti-JNK
antibodies from Cell Signaling Technology (Beverly, MA, USA); anti-
phospho-tyrosine (clone 4G10) antibody from Upstate (Lake Placid,
NY, USA); anti-FLAG-M2 antibody from Sigma-Aldrich (St. Louis, MO,
USA); anti-penta-His antibody from Qiagen (Cambridge, MA, USA);
anti-phospho-FLT-1 (Y1213) antibody from R&D Systems (Minneapolis,
MN, USA), and horseradish peroxidase-conjugated goat anti-mouse-IgG,
anti-rabbit-IgG or anti-human-Fc antibodies from KOMA Biotech (Seoul,
Korea). Rabbit anti-PTK7 anti-serum was described previously [24].
2.2. Cell culture
HUVECs were grown in M199 medium supplemented with 20% FBS
(Hyclone, South Logan, UT, USA), 5 U/ml heparin, and 3 ng/ml bFGF
(Upstate) and were used in passages 5–8. Human embryonic kidney
(HEK) 293 cell lines were grown in DMEM supplemented with 10% bo-
vine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin. All cells
were grown at 37 °C in 5% CO2.
2.3. Expression and knockdown vectors
pRSET-A-KDR harboring human full-length kinase insert domain
receptor (KDR; VEGF receptor 2) cDNA and pCI-Neo-FLT-1 encoding
human fms-related tyrosine kinase 1 (FLT-1; VEGF receptor 1) were
a kind gift from Dr. Yong Song Gho (POSTECH, Korea). pcDNA3-
sKDR-Fc and pcDNA3-sFLT-1-Fc encoding the extracellular domain
of KDR (amino acids 1–764) and FLT-1 (amino acids 1–687) with a
C-terminal Fc fragment, respectively, were generous gifts from Dr. Gou
Young Koh (KAIST, Korea). Construction of the following expression
vectors is described in the Supplementary materials: pcDNA3-hPTK7-
FLAG encoding human PTK7 with a C-terminal Flag tag, pcDNA3-
PTK7-TM-Cyt-FLAG encoding transmembrane and cytosolic domains
of human PTK7 with a C-terminal Flag tag, and pcDNA3.1-Kozak-KDR
encoding human KDR. Constructs pLKO.1-shRNA-PTK7-6433 and
-6434 for human PTK7 knockdown vectors and pLKO.1-control
(Sigma-Aldrich) were described previously [20].
2.4. Transfection of expression and knockdown vectors
For stable expression in HEK293 cells, subconﬂuent cells were
transfected by the calcium phosphate method [25] and were grown in
the presence of 1.2 mg/ml G418 for two weeks. G418-resistant colonies
were isolated as individual clones or cultured asmixed populations. For
transient expression inHEK293 cells, transfectionwas performed by the
same procedures as for stable expression. For transient transfection into
HUVECs, subconﬂuent cells were transfected using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) according to themanufacturer's instruc-
tions. Transfected cells were used two days after transfection.2.5. Transfection of siRNA
siRNAmixture against human PTK7 was transfected into HUVECs as
described previously [24].
2.6. Puriﬁcation of sPTK7, sKDR, and sFLT-1
Puriﬁcation of human and mouse sPTK7 with a C-terminal His tag
(sPTK7-His) was previously described [24]. For puriﬁcation of human
sKDR and human sFLT-1 fused to a C-terminal Fc (sKDR-Fc and sFLT-
1-Fc), stable clones expressing sKDR-Fc or sFLT-1-Fc were cultured in
serum-free medium for seven days. The conditioned medium was sub-
jected to ammonium sulfate precipitation with 70% saturation. The pel-
lets were dissolved in 0.1 M Tris–HCl (pH 8.0) containing 1 mM PMSF
and 1 mM EDTA. Protein-A Sepharose (Sigma-Aldrich) was added to
the supernatant, washed with 0.1 M Tris–HCl (pH 8.0), and eluted
with 0.1 M glycine–HCl (pH 3.0). The eluent containing sKDR-Fc was
neutralized with 0.1 volume of 1 M Tris–HCl (pH 8.0) immediately
and dialyzed against PBS [137 mM NaCl, 10 mM Na2HPO4, 2.7 mM
KCl, 2 mM KH2PO4 (pH 7.4)] containing 1 mM PMSF.
2.7. Growth factor stimulation of HUVECs
Subconﬂuent HUVECs were serum-depleted in M199 medium sup-
plementedwith 1% FBS for 6 h. If necessary, the depleted cells were pre-
incubated with the indicated proteins for 30 min. The cells were
stimulated with 0.5 nM VEGF (KOMA Biotech), for 5 min for analysis
of receptors, or for 10 min for analysis of other signaling molecules.
2.8. Immunoprecipitation, pull-down assays and immunoblotting
Cells were lysed with lysis buffer (50 mM Tris–HCl, pH 7.4,
150 mM NaCl, 1% NP-40) containing 5 mM NaF, 1 mM Na3VO4, and
protease inhibitor cocktail III (Calbiochem, La Jolla, CA, USA). For im-
munoprecipitation, lysates were incubated with the indicated anti-
bodies and protein-A/G agarose (Upstate) or mouse anti-FLAG M2-
agarose. For pull-down assays, cell lysates and in vitro binding mix-
tures containing sPTK7-His, sKDR-Fc, or sFLT-1-Fc were incubated
with Ni2+-NTA agarose and protein-A Sepharose, respectively. The
protein-bound resins were washed with lysis buffer or, in the case
of the His-tag pull-down assay, with PBS containing 20 mM imidazole.
For immunoblotting, cell lysates or immunoprecipitated or pulled-
down proteins were resuspended in SDS-sample buffer, subjected to
SDS-PAGE, and transferred to PVDF membranes. Immunoblotting was
performed using the indicated antibodies, and immunoreactivity was
visualized using Immobilon Western Chemiluminescent HRP Substrate
(Millipore, Bedford, MA, USA) and a LAS-3000 imaging system (Fuji,
Tokyo, Japan).
2.9. Chemotactic migration assay and capillary-like tube formation
These assays were performed as described previously [24] except
that migration and tube formation assays were incubated for 4 h and
24 h, respectively.
2.10. Ethics statement
The protocol for animal studies was approved by the Institutional
Animal Care and Use Committee of Yonsei University (Permit Number:
20130100). Animal studies were performed in accordance with the
guidelines of the Committee.
2.11. In vivo Matrigel plug assay
Ice-cold Matrigel™ (BD Biosciences, Bedford, MA, USA) (0.25 ml)
was mixed with 16 units of heparin, 2.5 nM mouse VEGF (KOMA
2253W.-S. Shin et al. / Biochimica et Biophysica Acta 1853 (2015) 2251–2260Biotech), and the indicated amounts of mouse sPTK7. The mixed
Matrigel was injected subcutaneously into the abdomens of 7-week-
old female C57BL/6 mice. After 9 days, the mice were killed, and the
plugs were recovered. Blood vessel formation in the plugs was quanti-
ﬁed by measurement of hemoglobin contents using a Drabkin reagent
kit 525 (Sigma-Aldrich).2.12. Statistical analysis
All data were based on at least three independent experiments and
expressed asmean±standard deviation. Statistical signiﬁcancewas an-
alyzed by Student's t-test.Fig. 1. Effect of sPTK7 or PTK7 knockdown on VEGF-induced phosphorylation of signaling mole
FBS for 6 h andpretreatedwith 53nM(4 μg/ml) sPTK7 for 30min. (B)HUVECs inwhich PTK7w
FBS for 6 h. The cells were stimulated with 0.5 nM VEGF for 5 min to analyze phosphorylation
phorylation levels of KDR and FLT-1 were analyzed by immunoprecipitation of cell lysates and
with anti-phospho-KDR (Y951) and anti-phospho-FLT-1 (Y1213). Silencing of PTK7 and phosph
anti-PTK7, anti-phospho-Akt (S473), anti-phospho-eNOS (S1177), anti-phospho-ERK, anti-pho
experiments are shown. Phosphorylation levels of VEGF receptors were estimated by densit
**P b 0.01 and ***P b 0.001 vs. a sample treated with VEGF alone.3. Results
3.1. Blocking endogenous PTK7 function inhibits VEGF-induced KDR
activation
To examine the role of PTK7 in VEGF-induced signaling pathways
in HUVECs, endogenous PTK7 function was counteracted by treatment
with a high concentration of the puriﬁed sPTK7 (53 nM or 4 μg/ml, Sup-
plementary Fig. 1) (Fig. 1A and Supplementary Fig. 2A) or knockdown
of PTK7 (Fig. 1B and Supplementary Fig. 2B). Blocking PTK7 function
inhibited VEGF-induced phosphorylation of KDR, Akt, eNOS, and ERK,
but not the phosphorylation of FLT-1, JNK, and p38MAPK. These results
imply that PTK7 plays a role in the activation of KDR but not of FLT-1.cules in HUVECs. (A) Subconﬂuent HUVECs were starved in M199medium containing 1%
as silenced by transfection of siRNAswere starved inM199medium supplementedwith 1%
of receptors or for 10 min to analyze phosphorylation of other signaling molecules. Phos-
immunoblotting using an anti-phospho-tyrosine antibody (A) or by immunoblot analysis
orylation levels of other signalingmolecules were examined by immunoblot analysiswith
spho-p38, and anti-phospho-JNK antibodies. Representative data from three independent
ometry. Graphs show the relative levels of receptor phosphorylation ([phospho-R]/[R]).
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main of KDR
To understand how PTK7 increases phosphorylation of KDR, the
interaction between PTK7 and VEGF receptors was analyzed by pull-Fig. 2.Analysis of the interaction of PTK7with VEGF receptors inHUVECs andHEK293 cells. (A)
panel) were lysed. Lysates were immunoprecipitated with anti-PTK7 antibody or IgG and prot
expressing KDR-HA (B) or FLT-1 (C). (D) HEK293 cells expressing KDR-HA were incubated wi
PTK7-TM-Cyt-FLAG was transfected into HEK293 cells expressing KDR-HA. PTK7-FLAG (B, C
FLAG antibody-conjugated agarose. sPTK7-His (D) was pulled down with Ni2+-NTA agarose.
down proteins (9/10 of lysates for HUVECs and 19/20 of lysates for HEK293 cells) were subj
anti-FLT-1 (A, C), anti-HA (B, D), anti-penta-His (D), anti-FLAG (B, C, E), and anti-β-actin antibdown assays in HUVECs which endogenously express KDR and FLT-1
as well as PTK7. KDR was co-precipitated with PTK7 but FLT-1 was not
(Fig. 2A left panel). After silencing of PTK7 in HUVECs, KDR was not
detected in the immunoprecipitate by anti-PTK7 antibody (Fig. 2A
right panel). Moreover, in HEK293 cells ectopically expressing PTK7HUVECs (left panel) or HUVECs inwhich PTK7was silencedby transfection of siRNAs (right
ein-A Sepharose. (B, C) A PTK7-FLAG expression vector was transfected into HEK293 cells
th DMEM containing 53 nM sPTK7-His for 2 h at 4 °C. (E) An expression vector encoding
) and PTK7-TM-Cyt-FLAG (E) were immunoprecipitated from the cell lysates with anti-
Cell lysates (1/10 of lysates for HUVECs and 1/20 of lysates for HEK293 cells) and pulled-
ected to SDS-PAGE and analyzed by immunoblotting with anti-KDR (A), anti-PTK7 (A),
odies. Representative data from three independent experiments are shown.
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FLAG) was co-precipitated with HA-tagged KDR (KDR-HA) but not
with FLT-1 (Fig. 2B and C).
To determine which domain of PTK7 interacts with KDR, HEK293
cells overexpressing KDR-HA were treated with puriﬁed His-tagged
sPTK7 (sPTK7-His) or co-expressed with a FLAG-tagged PTK7 fragment
containing the transmembrane and cytosolic domains (PTK7-TM-Cyt-
FLAG). Pull-down assay showed that sPTK7 interacted with KDR
(Fig. 2D) but transmembrane and cytosolic domains of PTK7 did not
(Fig. 2E).
Binding speciﬁcity of PTK7 to KDR was further analyzed with puri-
ﬁed extracellular domains of PTK7 (sPTK7), KDR (sKDR; 160 kDa), and
FLT-1 (sFLT-1; 127 kDa) (Supplementary Fig. 1). sPTK7-His speciﬁcally
bound to sKDR-Fc but not to sFLT-1-Fc when sPTK7-His was incubated
with a mixture of sKDR-Fc and sFLT-1-Fc (Fig. 3).
3.3. A single sPTK7 molecule binds multiple molecules of KDR extracellular
domain (sKDR) in vitro, and vice versa
To further characterize the interaction between sPTK7 and sKDR, the
binding kinetics of sPTK7-His and sKDR-Fc were analyzed in vitro. Bind-
ing of sKDR-Fc to sPTK7-His (Fig. 4A) or of sPTK7-His to sKDR-Fc
(Fig. 4B) was enhanced by increasing concentrations of sKDR-Fc and
sPTK7-His, respectively. Saturation of the interactions was detected at
input molar ratios of 1:8 and 8:1 of sPTK7 to sKDR. At saturation, the
molar ratio of the bound molecule to the pulldown molecule was
approximately 1:3, indicating that one molecule of sPTK7 binds to
three molecules of sKDR, and vice versa.
3.4. sPTK7 modulates the interaction of sKDR and VEGF in vitro
To analyze the effect of sPTK7 on the VEGF–sKDR interaction, sKDR-
Fc was preincubated with sPTK7 at molar ratios of 1:0, 1:0.25, 1:1, and
1:4, followed by incubation with increasing amounts of VEGF. Next, the
amount of VEGF which co-precipitated with sKDR-Fc was determined.Fig. 3. Interaction of sPTK7 with extracellular domains of VEGF receptors in vitro. Puriﬁed
sPTK7-His (2.5 pmol) was incubated with a mixture of sKDR-Fc (10 pmol) and sFLT-1-Fc
(10 pmol) in 100 μl of a binding buffer (PBS containing 20 mM imidazole, 0.1% Triton X-
100, and 0.01% BSA) for 2 h at 4 °C. Proteins pulled-downwith Ni2+-NTA agarose and con-
trols (0.25 pmol each)were subjected to SDS-PAGE and analyzed by immunoblottingwith
anti-human Fc and anti-penta-His antibodies.As expected, in the absence of sPTK7, increased VEGF concentrations
resulted in increased VEGF–sKDR interaction (Fig. 5, [sPTK7]/[sKDR] =
0). Interestingly, preincubation of sKDR with sPTK7 at the 1:0.25 molar
ratio enhanced VEGF–sKDR binding (Fig. 5, [sPTK7]/[sKDR] = 0.25).
However, preincubation of sKDR with higher concentrations of sPTK7
(1:1 and 1:4 molar ratios) drastically decreased binding of VEGF to
sKDR, (Fig. 5, [sPTK7]/[sKDR] = 1 and 4). Together with the data in the
previous section (Fig. 4), these results show that when single molecules
of sPTK7 bind several molecules of sKDR, the complexes bind more efﬁ-
ciently to VEGF than sPTK7-free sKDR. In contrast, when several mole-
cules of sPTK7 bind to individual molecule of sKDR, the complexes bind
less efﬁciently to VEGF.3.5. sPTK7 modulates VEGF-induced KDR phosphorylation in HUVECs
sPTK7 is able to oligomerize sKDR and, at lowermolar ratios to sKDR,
enhances binding of VEGF to sKDR. However, at higher concentrations,
it inhibits binding of VEGF to sKDR. In addition, we previously showed
that treatment with a high concentration (53 nM; 4 μg/ml) of sPTK7
inhibited VEGF-induced physiological effects in HUVECs and angiogen-
esis in vivo [24]. To understand the effect of sPTK7 concentration onKDR
activation, we analyzed VEGF-induced KDR phosphorylation in HUVECs
in response to increasing amounts of sPTK7 (Fig. 6A). KDR phosphoryla-
tion levels gradually increased upon incubation of sPTK7 up to 0.5 nM,
but, upon treatment with higher concentrations of sPTK7, decreased
below the basal level without sPTK7 treatment. This pattern persisted
when the experiment was replicated in HEK293 cells ectopically
expressing KDR (Supplementary Fig. 3A and B left panel). On the
other hand, as would be expected, phosphorylation of FLT-1 was not
affected by increasing concentrations of sPTK7 (Supplementary Fig. 3A
and B right panel).
The effect of sPTK7 on KDR phosphorylation was also analyzed in
PTK7-knockdown HUVECs (Supplementary Fig. 4). Again, under these
conditions, VEGF-induced KDR phosphorylation initially increased,
and then decreased with increasing amounts of sPTK7 (Fig. 6B). In
PTK7-knockdown HUVECs, however, the maximal effect was detected
at 2 nM sPTK7, whereas the maximal effect was at 0.5 nM in PTK7-
positive HUVECs. This was also the case with KDR-expressing HEK293
cells or PTK7-knockdown HEK293 cells (Supplementary Fig. 3B left
panel and 3C). This result demonstrates that increasing concentrations
of sPTK7 modulate VEGF-induced activation of KDR biphasically
and suggests that a concentration of sPTK7 and/or PTK7 which induces
the most efﬁcient oligomerization of KDR molecules activates KDR
maximally.3.6. sPTK7modulates VEGF-induced cell migration and in vivo angiogenesis
To observe whether modulation of KDR activation by sPTK7 led to
changes in cell physiology, we analyzed the effect of sPTK7 on VEGF-
induced migration of HUVECs (Fig. 6C). In this assay, cell migration
was enhanced by increasing amounts of sPTK7, being highest in the
presence of 0.5 nM sPTK7, and then decreased upon treatment with
higher concentrations of sPTK7.
To examinewhether increasingdoses of sPTK7 affected angiogenesis
in vivo, a Matrigel plug assay was performed in mice. To detect an
increase in angiogenesis, we used a lower concentration (2.5 nM)
of VEGF, compared with 10 nM in typical assays. After incubation
in mice, plugs treated with VEGF alone were red-orange in color.
Increasing concentrations of sPTK7 made the plugs darken in color
up to 0.5 nM sPTK7, and then lighten with higher sPTK7 concentra-
tions (Fig. 6D). Hemoglobin content also followed the same pattern
(Fig. 6E). These results demonstrate that VEGF-induced cell migra-
tion and angiogenesis are also regulated biphasically in a sPTK7
concentration-dependent manner.
Fig. 4.Binding ratio of sPTK7 and sKDR in vitro. sPTK7-His (A) and sKDR-Fc (B) (2.5 pmol)were incubatedwith the indicatedmolar ratios of sKDR-Fc (A) and sPTK7-His (B), respectively, in
100 μl of the binding buffer for 2 h at 4 °C. Proteins pulled-downwith Ni2+-NTA agarose or protein-A Sepharose and controls (0.25 pmol each) were subjected to SDS-PAGE and analyzed
by immunoblotting with anti-human Fc and anti-penta-His antibodies. Representative data from three independent experiments are shown. Protein amounts in the immunoblots were
quantiﬁed by densitometry andwere normalizedwith standard curves for sKDR-Fc and sPTK7-His. Graphs giving the relative ratios of [bound sKDR]/[sPTK7] or [bound sPTK7]/[sKDR] are
shown below representative data.
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formation are controlled by the PTK7 expression level in HUVECs
Next,we analyzedwhether VEGF-induced KDR-activationwasmod-
ulated by expression of full-length PTK7, rather than treatment with
sPTK7. To alter PTK7 expression levels in HUVECs, PTK7 was eitherFig. 5. Effect of sPTK7 on binding of VEGF to sKDR in vitro. sKDR-Fc (10 pmol) was pre-incubat
creasing amounts of VEGF (0, 2.5, 5, 10, or 20 pmol) in 100 μl of the binding buffer for 5 min
(0.25 pmol each) were analyzed by immunoblotting with anti-human Fc, anti-penta-His, an
shown. Amounts of proteins in the immunoblots were quantiﬁed by densitometry and normaliz
of [bound VEGF]/[sKDR] vs. input ratios of [VEGF]/[sKDR]. Compared to determinants at [sPTK7gradually silenced by transfection with increasing amounts of PTK7
knockdown vector (pLKO.1-shRNA-PTK7) or gradually overexpressed
by transfection with increasing amounts of PTK7 expression vector
(pcDNA3-PTK7-FLAG). In response to increasing levels of PTK7 expres-
sion, VEGF-induced phosphorylation of KDR initially increased, and
then decreased (Fig. 7A).ed with sPTK7-His (0, 2.5, 10, or 40 pmol) for 2 h, and the mixture was incubated with in-
at 4 °C with gentle agitation. Proteins pulled-down by protein-A Sepharose and controls
d anti-VEGF antibodies. Representative data from three independent experiments are
edwith standard curves for sKDR-Fc, sPTK7-His, and VEGF. The graph shows relative ratios
]/[sKDR] = 0, all values were statistically signiﬁcant (P b 0.05).
Fig. 6. Effect of increasing amounts of sPTK7 onVEGF-induced KDR phosphorylation and cellmigration inHUVECs and angiogenesis inmice. (A, B)HUVECswere transfectedwith a control
vector (A) or a PTK7 knockdown vector (B). The HUVECs were starved in a medium containing 1% FBS for 6 h. Theywere preincubatedwith the indicated amounts of sPTK7 for 30min at
37 °C, and then stimulatedwith VEGF for 5min. Phosphorylation of KDRwas analyzed by immunoblottingwith anti-phospho-KDR (Y951), anti-KDR, anti-PTK7, and anti-β-actin antibod-
ies. (C) StarvedHUVECswere detachedwith trypsin and incubatedwith the indicated amounts of sPTK7 for 30min. VEGF-induced chemotacticmigration of the cells was analyzed using a
Transwell chamber (n= 3). (D, E)Matrigel wasmixedwith 16 units of heparin, and either 2.5 nMmouse VEGF or VEGF plus the indicated amounts ofmouse sPTK7, and injected into the
abdomens of mice subcutaneously (3 plugs per group). After 9 days, the plugs were recovered. Representative images of theMatrigel plugs (D) andmeasurements of hemoglobin content
in the Matrigel plugs (E) are shown. ††P b 0.01 and †††P b 0.001 vs. non-VEGF-treated control, *P b 0.05, **P b 0.01, and ***P b 0.001 vs. a sample treated with VEGF alone.
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capillary-like tube formation of HUVECs. In agreement with the pattern
of VEGF-induced KDR phosphorylation, increasing amounts of PTK7
ﬁrst increased and then decreased both cell migration (Fig. 7B) and
tube formation (Fig. 7C and D). The highest levels of cell migration
and tube formation, as well as of KDR phosphorylation, were achieved
when HUVECs were transfected with 1 μg of PTK7 expression vector.
4. Discussion
Wepreviously showed that treatment of HUVECswith a high dose of
sPTK7 (6.25 to 53 nM) inhibited VEGF-inducedmigration, invasion, and
tube formation in a dose-dependent manner [24]. Dana and colleagues
reported that PTK7 knockdown inhibited VEGF-induced phosphoryla-
tion of FLT-1, but not KDR, in mouse endothelial MS1 cells and that
PTK7 interacted with FLT-1, but not with KDR or FLT-4 [26]. In contrast,
we found that treatment of HUVECs with a high dose of sPTK7 (53 nM)
or knockdownof PTK7 inhibitedVEGF-induced phosphorylation of KDR,
but not FLT-1. In HUVECs and HEK293 cells expressing PTK7 and aspeciﬁc RPTK, KDR co-precipitated with PTK7, but FLT-1 did not. More-
over, we demonstrated that PTK7 and KDR interacted through their
extracellular domains in vitro and in cells. Therefore, PTK7 plays a role
in angiogenesis by controlling activation of KDR.
Terman and colleagues found that deletion of the 4th to 7th immu-
noglobulin domains of KDR led to VEGF-independent receptor activa-
tion [27]. Ballmer-Hofer and colleagues reported that the afﬁnity of
VEGF165 for sKDRwas 6–21-fold lower than for the 2nd and 3rd immu-
noglobulin domains of KDR, as assessed by thermodynamic analysis
[28]. These results suggest that the presence of the 4th to 7th immuno-
globulin domains of KDR inhibits ligand-independent KDR dimerization
and kinase activation. In fact, negative-staining electron microscopy
revealed that ligand-free sKDR molecules are present as ﬂexible mono-
mers [29]. Interestingly, we found above using an in vitro binding assay
that sPTK7 could form ligand-free hetero-oligomers with sKDR. Maxi-
mally, 2.76 sKDR molecules interacted with a single PTK7 molecule at
a molar ratio of sPTK7 to sKDR higher than 1:8. In serum-depleted
HUVECs, the molar ratio of PTK7 to KDR is 1:3.6 (13.0 × 10−18 mol of
PTK7 molecules and 46.6 × 10−18 mol of KDR molecules per cell)
Fig. 7. Effect of increasing levels of PTK7 expression on VEGF-induced KDR phosphorylation, cell migration, and capillary-like tube formation in HUVECs. HUVECs were transfected with
increasing amounts of PTK7 knockdown vector (pLKO.1-shRNA-PTK7-6434; shRNA-PTK7) or PTK7 expression vector (pcDNA3-PTK7-FLAG; PTK7). After 48 h, theHUVECswere starved in
amediumcontaining 1% FBS for 6 h. (A) The cellswere stimulatedwith 0.5 nMVEGF for 5min, and the phosphorylation of KDRwas examinedby immunoblotting using anti-phospho-KDR
(Y951), anti-KDR, anti-PTK7, and anti-β-actin antibodies. (B, C, D) The cells were detached and subjected to a VEGF-induced chemotactic migration assay (B) or a capillary-like tube for-
mation assay (C) as described previously [24]. Representative lightmicrographs of the capillary-like tube formation assay are shown in (C) (Magniﬁcation, 60×). Tube numbers in (C)were
counted and plotted in (D). †††P b 0.001 vs. non-VEGF-treated control, **P b 0.01, ***P b 0.001 vs. HUVECs treated with VEGF alone.
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late ligand-free oligomerization of KDR molecules on the cell surface.
In addition to the role of PTK7 in KDR oligomerization, the presence
of sPTK7 at molar ratios lower than sKDR (for example, 0.25:1 input
molar ratio of sPTK7 to sKDR) enhanced binding of VEGF to sKDR, com-
pared with the absence of sPTK7. Since VEGF did not bind to sPTK7
(Supplementary Fig. 6), we suggest that sKDR bound to sPTK7 has a
higher afﬁnity for VEGF due to a conformational change. In contrast, at
higher levels of PTK7 (higher than 1:8 molar ratios of sKDR to sPTK7),
one sKDR molecule can form hetero-oligomers involving up to three
sPTK7 molecules. In addition, when sPTK7 was present at the same ora higher molar concentration than sKDR, the enhancement of VEGF–
sKDR binding by sPTK7 was diminished.
Based on our ﬁndings, we propose a model for the role of PTK7
in modulating KDR activation (Fig. 8). At lower molar ratios, PTK7
enhances KDR signaling by oligomerization of KDR and this increases
binding of VEGF to the KDR oligomers. The increased VEGF–KDR bind-
ing is probably due to a PTK7-induced conformational change of KDR
that increases its afﬁnity for VEGF and/or to increased local concentra-
tions of KDR resulting from its hetero-oligomerization. Conversely, at
higher molar ratios, PTK7 inhibits activation of KDR because the KDR
molecules are enclosed by PTK7 molecules and, therefore, cannot bind
Fig. 8.Amodel for themodulation of KDR activity via PTK7. In the absence of PTK7 (blue), KDRmolecules (red) can be dimerized and activated by VEGF dimers (green). In the presence of
PTK7 at concentrations lower than the KDR concentration, one PTK7 molecule can bind together up to three ligand-free KDR molecules. Due to a PTK7-mediated conformational change
and/or the increased local concentrations of KDR molecules, the PTK7-bound KDR molecules readily bind to the VEGF dimers and are activated. However, when PTK7 is present at much
higher concentrations than KDR, each KDRmolecule is enclosed by several PTK7molecules and cannot bind to the VEGF dimers. Overall, increasing levels of PTK7 thus result in an up-and-
down biphasic pattern of modulation of VEGF-induced KDR activation.
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similar to a previously proposed model for increased MAPK activation
by a scaffold protein [30]. In the model, at lower concentrations, the
scaffold protein recruits signaling components and increases output sig-
naling. However, at higher concentrations, scaffold proteins separate
the signaling components, inhibiting the signaling cascade. In both
models, the optimal concentration of PTK7 or scaffold protein is impor-
tant for maximal activation of signaling partners.
We hypothesized that increasing expression levels of PTK7 would
show an up-and-down biphasic pattern for VEGF-induced KDR activa-
tion in vivo. As expected, we found that increasing concentrations of
sPTK7 initially increases KDR activation in HUVECs, followed by a de-
crease. In normal HUVECs, 0.5 nM sPTK7 maximally activates the
VEGF-induced KDR phosphorylation. In HUVECs where PTK7 has been
knocked down, the maximal activation of VEGF-induced KDR phos-
phorylation requires a higher concentration of sPTK7 (2 nM). This result
suggests that the endogenous PTK7 level in HUVECs is sub-optimal (ap-
proximately 75%) for maximal KDR activation. The effect of sPTK7 on
VEGF-induced signaling was also seen in endothelial cells examined in
an in vivo angiogenesis assay. Moreover, our experiments exposing
HUVECs to a range of full-length PTK7 levels clearly demonstrated
that PTK7 modulated VEGF-induced physiological events, such as KDR
activation, chemotactic migration, and capillary-like tube formation of
HUVECs with a bell-shaped dose response curve.
We and others have shown that knockdown of PTK7 decreases pro-
liferation, survival, wound healing, and invasion of esophageal squa-
mous cell carcinoma cells [20] and reduces cell viability and tumor
burden in lung adenocarcinoma [31], demonstrating oncogenic roles
for PTK7. In contrast, we also noted a tumor-suppressive role of PTK7,as overexpression of PTK7 decreased cell proliferation, invasion, and
migration in lung squamous cell carcinoma [32]. These ﬁndings can be
explained with our model for a biphasic effect of PTK7 on RPTK activity,
because knockdown and overexpression of PTK7 would represent
extremes of the bell-shaped PTK7 dose–response curve.5. Conclusions
Our results suggest a novel mechanism for the biphasic regulation of
KDR activity by PTK7: at lower concentrations, PTK7 activates KDR by
promoting KDR oligomerization and so increasing its afﬁnity for the
ligand, and at higher concentrations, PTK7 inhibits the pathway by sur-
rounding KDR. Our ﬁndings concerning the role of PTK7 in activation of
KDR should contribute to controlling diseases involving KDR, such as
pathological angiogenesis.Transparency document
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